An Overview of Candidate Therapeutic Target Genes in Ovarian Cancer

Cancers
Elena AlexandrovaRoberta Tarallo

Abstract

Ovarian cancer (OC) shows the highest mortality rate among gynecological malignancies and, because of the absence of specific symptoms, it is frequently diagnosed at an advanced stage, mainly due to the lack of specific and early biomarkers, such as those based on cancer molecular signature identification. Indeed, although significant progress has been made toward improving the clinical outcome of other cancers, rates of mortality for OC are essentially unchanged since 1980, suggesting the need of new approaches to identify and characterize the molecular mechanisms underlying pathogenesis and progression of these malignancies. In addition, due to the low response rate and the high frequency of resistance to current treatments, emerging therapeutic strategies against OC focus on targeting single factors and pathways specifically involved in tumor growth and metastasis. To date, loss-of-function screenings are extensively applied to identify key drug targets in cancer, seeking for more effective, disease-tailored treatments to overcome lack of response or resistance to current therapies. We review here the information relative to essential genes and functional pathways recently discovered in OC, often strictly interconnected with...Continue Reading

References

Aug 19, 1991·International Journal of Cancer. Journal International Du Cancer·S FranceschiD Trichopoulos
Feb 1, 1990·Nature·J L Goldstein, M S Brown
Oct 1, 1994·American Journal of Epidemiology·H A RischG R Howe
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·C M CounterC B Harley
Dec 15, 1995·Cell·D J MangelsdorfR M Evans
Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J W Shay, S Bacchetti
May 3, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F ChiaffarinoC La Vecchia
Aug 13, 2002·Anti-cancer Drugs·Yasumasa KunifujiYuji Karasaki
Dec 12, 2002·Steroids·Deborah A Lannigan
May 22, 2003·Cancer Letters·Gabriele Saretzki
May 29, 2004·Mutation Research·Andrej Dudás, Miroslav Chovanec
Jun 24, 2004·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·C Blake Gilks
Aug 19, 2004·Acta Obstetricia Et Gynecologica Scandinavica·Tomas RimanIngemar R Persson
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kristin K ZornMichael J Birrer
Jan 24, 2007·American Journal of Obstetrics and Gynecology·Claudio PelucchiCarlo La Vecchia
May 22, 2007·Cell·George-Lucian MoldovanStefan Jentsch
Jun 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John F SmythSimon P Langdon
Jun 23, 2007·Nature Reviews. Drug Discovery·Panagiotis A KonstantinopoulosAthanasios G Papavassiliou
Aug 19, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R SalaniI-M Shih
Oct 19, 2007·Pharmacoepidemiology and Drug Safety·Gary D FriedmanLaurel A Habel
Nov 17, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Catherine M OlsenUNKNOWN Australian Ovarian Cancer Study Group
Dec 25, 2007·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Javier de la TorreRaimundo Freire
Jan 2, 2008·Cell Research·Xuan Li, Wolf-Dietrich Heyer
Feb 27, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·E J Nam, Y T Kim
Apr 9, 2008·American Journal of Obstetrics and Gynecology·Steven C Plaxe
Sep 13, 2008·Traffic·Letizia Lanzetti, Pier Paolo Di Fiore
Oct 3, 2008·Genome Biology·Huawei XinZhou Songyang
Oct 10, 2008·Annual Review of Pathology·Kathleen R Cho, Ie-Ming Shih
Nov 13, 2008·Cytotechnology·Kunal P Patel, Robert H Vonderheide
Dec 2, 2008·Cancer Causes & Control : CCC·Onchee YuDiana L Miglioretti
Dec 6, 2008·International Journal of Cancer. Journal International Du Cancer·Whitney A SpannuthAnil K Sood
Apr 23, 2009·Molecular Oncology·Henry T LynchAndrew K Godwin
Sep 19, 2009·Cancer Treatment and Research·Kwai Wa ChengGordon B Mills
Nov 17, 2009·American Journal of Epidemiology·Margaret A GatesShelley S Tworoger
Oct 15, 2010·Molecular Cancer·Véronique BarrèsAnne-Marie Mes-Masson
Nov 26, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Matthew P SchlumbrechtRussell R Broaddus

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
hormone replacement therapy
deamination
xenografts
GTPase
RNA-Seq
xenograft
GTPases
antisense oligonucleotides

Software Mentioned

DepMap
cBioPortal

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [et Al.]
Alba MotaGema Moreno-Bueno
The International Journal of Biochemistry & Cell Biology
Hamideh AboutalebiSeyed Mahdi Hassanian
© 2022 Meta ULC. All rights reserved